This dependence on the CDK4 pathway resulted in a potential therapeutic approach to combine MEK and CDK4 inhibitors to target different tumor subpopulations along the EMT spectrum and combat resistant outgrowth of epigenetic subsets in a heterogeneous tumor. The gene discussed is MAP2K7; the disease is neoplasm.